Literature DB >> 6110850

Bromocriptine for levodopa-induced end-of-dose dystonia.

M Hallett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6110850     DOI： 10.1016/s0140-6736(81)92066-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Dysregulation of striatal dopamine release in a mouse model of dystonia.

Authors:  Li Bao; Jyoti C Patel; Ruth H Walker; Pullanipally Shashidharan; Margaret E Rice
Journal:  J Neurochem       Date:  2010-07-27       Impact factor: 5.372

Review 2.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  Commentary: Dopaminergic dysfunction in DYT1 dystonia.

Authors:  Thomas Wichmann
Journal:  Exp Neurol       Date:  2008-04-26       Impact factor: 5.330

4.  Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice.

Authors:  D M Jackson; S B Ross; M Hashizume
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.